The Joint Commission Perspectives on Patient SafetyTM, April, 2008 Newsletter - Implementing National Patient Safety Goal Requirement 3E: A Model Plan
New for 2008, The Joint Commission has released National Patient Safety Goal Requirement 3E: Reduce the Likelihood of patient harm associated with the use of anticoagulation therapy. Based on medication error data compiled by the United States Pharmacopeia (USP), warfarin has been identified as 1 of the 10 drugs most commonly involved in medication errors in hospitals.
CoagClinic™ Offers Effective Tool to Meet New Joint Commission 3E Requirement for Anticoagulation Therapy Management
Disease Management Software Implements Comprehensive Guidelines While Improving Patient Safety and Lowering Costs
WESTPORT, CT -- (Business Wire) –-
February 28, 2008
Standing Stone, Inc., a leader in disease state management solutions, announces that its CoagClinic™ software application is helping hospitals, clinics and other healthcare facilities meet the expansive new Joint Commission 3E Requirement for inpatient and outpatient anticoagulation therapy management which became effective January 1st.
Standing Stone’s CholesterolClinic™ V3.2 Delivers Improved Patient Outcomes and Cost Savings for Cholesterol Therapy Management
Full-Featured Clinical Decision Support Software Benefits Both Patients and Healthcare Providers
December 17, 2007
Standing Stone, Inc., a leader in disease state management solutions, announces the release of its CholesterolClinic™ software Version 3.2 with significantly expanded reporting and user functionality. The enhanced user interface provides the most comprehensive, easy-to-use cholesterol clinical decision support solution available to healthcare professionals today.
Standing Stone’s CoagClinic™ Improves Patient Safety and Reduces Costs for Anticoagulation Therapy Management: Disease Management Software Helps to Reduce Adverse Events by 89%
WESTPORT, CT -- (Business Wire) --December 3, 2007
Standing Stone, Inc., a leader in disease state management solutions, announces that its CoagClinic™ software application can help hospitals, clinics and other healthcare facilities significantly improve patient safety in anticoagulation management. The software will also help these institutions meet stringent new Joint Commission 3E requirements for inpatient and outpatient anticoagulation therapy management, effective January 1, 2008.
National Experience with an Electronic Medical Record for Anticoagulation Therapy Abstract Presented at 2007 Anticoagulation Forum
CHICAGO, Il.May 31, 2007
The following abstract was presented at the 8th Anticoagulation Forum in Chicago, Illinois in May of 2007. The full paper will be published in 2008. This study, which used CoagClinic, examined over 130 systems nationwide and included over 1.1 million patient encounters to determine overall compliance rates for anticoagulation therapy.
Standing Stone Takes In $1M Series B Round
WESTPORT, Ct. --(VENTURE WIRE)--Mar. 21, 2007
Standing Stone Inc., a developer of chronic disease care management software, has raised a $1 million Series B round.
Connecticut Innovations put in $700,000 toward the Series B, with the remaining funding provided through existing angel investors.
Connecticut Innovations Completes $700,000 Investment in Standing Stone Inc.
ROCKY HILL, Ct. --(CONNECTICUT INNOVATIONS)--Mar. 19, 2007
Connecticut Innovations (CI), the state’s quasi-public authority responsible for technology investing and innovation development, today announced that it has completed an investment of $700,000 in Standing Stone Inc. (SSI) of Westport, Connecticut. CI led a $1.0 Series B round which also involved prior investors.
Standing Stone Signs Co-Marketing Agreement with HemoSense to Offer Connectivity Solution for INRatio
SAN JOSE, Calif. and WESTPORT, Ct. --(BUSINESS WIRE)--
Oct. 20, 2005
Standing Stone is pleased to announce that it has signed a co-marketing
agreement with HemoSense, Inc. (AMEX:HEM) today to promote the use of
Standing Stone's web-based CoagClinic(TM) software with HemoSense's
INRatio® PT/INR Monitor. Together CoagClinic and INRatio can offer health
care professionals a comprehensive PT/INR testing, documentation, and
management system for anticoagulation patients taking warfarin, a
blood-thinning drug. Under the agreement the companies will develop
co-branded advertising, joint marketing materials, and co-promotional sales
initiatives in the United States. For more information on HemoSense,
please visit them at www.hemosense.com
Missouri PRO Article Shows Office-Based Comprehensive Anticoagulation Program Can Pay-Off
A published article in the Missouri PRO HCQIP Newsletter (Volume 9, Number 3, July 2001), shows that a primary care environment, using CoagClinic and a point of care testing device, was able to significantly increase patient compliance rates for INR's as well as improve the financial situation of their clinic. The hospital system saved $2,700 per patient enrolled in the anticoagulation management program as well as improved therapeutic time in range by 97%. The system generated $25 for each $1 spent on on implementation and maintenance.
CoagClinic Study Published in CHEST.
A clinical study using CoagClinic was published in CHEST, the journal of the American College of Chest Physicians. The study results showed that through the use of CoagClinic in conjunction with a Point of Care testing device, INR compliance rates were significantly improved (48% to 71%) while operational and complication costs were significantly decreased. Please contact Standing Stone for a copy of the abstract.
49 Richmondville Avenue, Westport, CT 06880 Tel: (800) 648-9877 E-mail: info@standingstoneinc.com
